Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1059

—

ac3dadb0-8e09-5ad8-acda-992d8d49a0d6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.518
  • TGF_BETA_SIGNALING+0.480
  • PROTEIN_SECRETION+0.467
  • ANDROGEN_RESPONSE+0.458
  • CHOLESTEROL_HOMEOSTASIS+0.411
  • HEME_METABOLISM+0.383
  • ESTROGEN_RESPONSE_EARLY+0.376
  • ESTROGEN_RESPONSE_LATE+0.366
  • UV_RESPONSE_DN+0.359
  • HYPOXIA+0.346

Top 10 suppressed

  • MYC_TARGETS_V2-0.391
  • ALLOGRAFT_REJECTION-0.272
  • E2F_TARGETS-0.252
  • WNT_BETA_CATENIN_SIGNALING-0.083
  • DNA_REPAIR-0.075
  • OXIDATIVE_PHOSPHORYLATION-0.073
  • INTERFERON_ALPHA_RESPONSE-0.054
  • G2M_CHECKPOINT-0.028
  • PI3K_AKT_MTOR_SIGNALING+0.047
  • UNFOLDED_PROTEIN_RESPONSE+0.066

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG967
mng-umap@100
——0.826
2MNG1023
mng-umap@100
——0.821
3TCGA-60-2707-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.820
4106E2A94-0366-4D5E-894F-41117C78E18C
brain-umap@2
——0.819
520030016.LumA
breast-umap@18
—B0.814
6TCGA-96-7545-01A-21R-2045-07
lung-landscapes@6
—cohortSQ20.814
7TCGA-A1-A0SJ-01A-11R-A084-07
breast-umap@18
—B0.804
8SNU886_LIVER
ccle-hcc@v2024.1
HCC—0.801
9MNG1172
mng-umap@100
——0.797
10MNG223
mng-umap@100
——0.789

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 42 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.518Inavolisib— uncovered
TGF_BETA_SIGNALING0.480Inavolisib— uncovered
PROTEIN_SECRETION0.467Remibrutinib— uncovered
ANDROGEN_RESPONSE0.458Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.411Remibrutinib— uncovered
HEME_METABOLISM0.383Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.376Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.366Idelalisib— uncovered
UV_RESPONSE_DN0.359Inavolisib— uncovered
HYPOXIA0.346Idelalisib— uncovered
APOPTOSIS0.310Idelalisib— uncovered
ANGIOGENESIS0.295Remibrutinib— uncovered
APICAL_JUNCTION0.289Inavolisib— uncovered
BILE_ACID_METABOLISM0.285Inavolisib— uncovered
PEROXISOME0.261Idelalisib— uncovered
IL2_STAT5_SIGNALING0.241Idelalisib— uncovered
COAGULATION0.238Binimetinib— uncovered
MYC_TARGETS_V10.227Inavolisib— uncovered
HEDGEHOG_SIGNALING0.226Inavolisib— uncovered
FATTY_ACID_METABOLISM0.217Inavolisib— uncovered